Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.
Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans TR, Stocken D, Stubbs C, Praseedom R, Ma YT, Davidson B, Neoptolemos J, Iveson T, Cunningham D, Garden OJ, Valle JW, Primrose J; BILCAP study group. Bridgewater J, et al. Among authors: evans tr. J Clin Oncol. 2022 Jun 20;40(18):2048-2057. doi: 10.1200/JCO.21.02568. Epub 2022 Mar 22. J Clin Oncol. 2022. PMID: 35316080 Clinical Trial.
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Sarker D, Plummer R, Meyer T, Sodergren MH, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DRC, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra V, Nicholls JP, Collin D, Nutbrown R, Glenny H, Fairbairn S, Reebye V, Voutila J, Dorman S, Andrikakou P, Lloyd P, Felstead S, Vasara J, Habib R, Wood C, Saetrom P, Huber HE, Blakey DC, Rossi JJ, Habib N. Sarker D, et al. Clin Cancer Res. 2020 Aug 1;26(15):3936-3946. doi: 10.1158/1078-0432.CCR-20-0414. Epub 2020 May 1. Clin Cancer Res. 2020. PMID: 32357963 Clinical Trial.
Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.
Davis C, Tipton T, Sabir S, Aitken C, Bennett S, Becker S, Evans T, Fehling SK, Gunson R, Hall Y, Jackson C, Johanssen I, Kieny MP, Mcmenamin J, Spence E, Strecker T, Sykes C, Templeton K, Thorburn F, Peters E, Henao Restrepo AM, White B, Zambon M, Carroll MW, Thomson EC. Davis C, et al. Clin Infect Dis. 2020 Dec 31;71(11):2872-2879. doi: 10.1093/cid/ciz1165. Clin Infect Dis. 2020. PMID: 31784751 Free PMC article.
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I, Steven N, Lorigan P, Plummer R, Patel P, Psarelli E, Olsson-Brown A, Shaw H, Leyvraz S, Handley L, Rawcliffe C, Nathan P. Sacco JJ, et al. Among authors: evans trj. Eur J Cancer. 2024 May;202:114009. doi: 10.1016/j.ejca.2024.114009. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38547774 Free article. Clinical Trial.
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, Stamp G, Thompson L, Edmonds K, Sarker S, Banerji J, Lorigan P, Evans TRJ, Corrie P, Marshall E, Middleton MR, Nathan P, Nicholson S, Ottensmeier C, Plummer R, Bliss J, Valpione S, Turajlic S. Larkin J, et al. Among authors: evans trj. Cell Rep Med. 2024 Mar 19;5(3):101435. doi: 10.1016/j.xcrm.2024.101435. Epub 2024 Feb 27. Cell Rep Med. 2024. PMID: 38417447 Free PMC article. Clinical Trial.
A guide for social science journal editors on easing into open science.
Silverstein P, Elman C, Montoya A, McGillivray B, Pennington CR, Harrison CH, Steltenpohl CN, Röer JP, Corker KS, Charron LM, Elsherif M, Malicki M, Hayes-Harb R, Grinschgl S, Neal T, Evans TR, Karhulahti VM, Krenzer WLD, Belaus A, Moreau D, Burin DI, Chin E, Plomp E, Mayo-Wilson E, Lyle J, Adler JM, Bottesini JG, Lawson KM, Schmidt K, Reneau K, Vilhuber L, Waltman L, Gernsbacher MA, Plonski PE, Ghai S, Grant S, Christian TM, Ngiam W, Syed M. Silverstein P, et al. Among authors: evans tr. Res Integr Peer Rev. 2024 Feb 16;9(1):2. doi: 10.1186/s41073-023-00141-5. Res Integr Peer Rev. 2024. PMID: 38360805 Free PMC article.
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ. Yap C, et al. Among authors: evans trj. BMJ. 2023 Oct 20;383:e076387. doi: 10.1136/bmj-2023-076387. BMJ. 2023. PMID: 37863501 Free PMC article.
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.
Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Yap C, et al. Among authors: evans trj. BMJ. 2023 Oct 20;383:e076386. doi: 10.1136/bmj-2023-076386. BMJ. 2023. PMID: 37863491 No abstract available.
242 results